iLite® anti-CD20 ADCC Activity Set

Add to my product list

This product contains a packaged set of the three individual products, one vial of each:
iLite® ADCC Effector (V) Assay Ready Cells (BM4001), 
iLite® ADCC Target CD20 (+) Assay Ready Cells (BM4010) 
iLite® ADCC Target CD20 (-) Assay Ready Cells (BM4015)
All three products are genetically engineered human cells to be used for measuring the ADCC activity of anti-CD20 antibodies. For more information about the individual cell lines, please consult the specific Product Specifications on

Product code
Assay Ready Cells
Detection system
Research use only

The products included in the iLite® anti-CD20 ADCC Activity Set can be used together for the quantification ADCC activity of anti-CD20 antibodies. 
Application notes for the following assays are available:
Quantification of anti-CD20 ADCC activity (E-229-GB)

Antibody-dependent cell-mediated cytotoxicity (ADCC) is a mechanism whereby pathogenic cells are lysed by lymphocytes, most often Natural Killer (NK) cells. The mechanism involves binding of antibodies to surface antigens on the pathogen. Crosslinking of these antibodies to NK cells through the binding of the Fc-portion to Fc receptors on the NK cells leads to activation of the NK cell and formation of an immune synapse with the pathogenic cell. The NK cell releases cytotoxic granules containing granzymes and perforin into the synapse, leading to apoptosis of the targeted cell (1). 
The idea of employing ADCC to destroy dysfunctional cells by treating patients with antibodies has existed since the discovery of the ADCC mechanism. Rituximab, one of the first of such drugs approved, is a chimeric monoclonal antibody targeting CD20, a surface antigen primarily found on B-cells. The drug was approved by the FDA in 1997 for treatment of chemotherapy resistant Non-Hodgkin B-cell lymphomas, and has since also been approved in Europe for different inflammatory indications (2-4). 
In addition, other anti-CD20 monoclonal antibodies have been developed, such as ocrelizumab, a humanized (90-95%) antibody, and ofatumumab, a fully human monoclonal. In addition, efforts are being made to enhance the ADCC activity of the antibodies by engineering the glycan patterns of the constant region, such as in obinutuzumab (5). 

3 vials of iLite® Assay Ready Cells (>250 µL/vial) suspended in RPMI 1640 with 20% heat inactivated fetal bovine serum (FBS), mixed 1:1 with cryoprotective medium from Lonza (Cat. No 12-132A).